year left
june
immutep immp clinical-stag biotechnolog compani focus
develop relat immunotherapeut cancer auto-immun diseas
compani candid design use technolog leverag
uniqu immunostimulatori immunoinhibitori properti receiv
strong attent therapeut target follow phase i/iia oncolog data bristol-
myer squibb antibodi relatlimab immutep lead candid
develop three combin approach oncolog chemo-io combin io-
io combin vaccin adjuv multipl phase ii clinic trial on-going
immutep secur sever potenti revenue-gener partnership
collabor includ out-licens clinic asset novarti glaxosmithklin
point discuss
divers portfolio candid gener interest multipl
pharma compani immutep success leverag immunostimulatori
immunoinhibitori properti develop uniqu product candid
autoimmun diseas oncolog compani out-licens two clinical-
stage asset two big pharma compani out-
licens novarti nyse nv signific undisclos amount up-front
mileston payment out-licens glaxosmithklin nyse gsk
agreement make immutep elig mileston single-digit tier
royalti immutep also clinic trial collabor larg pharma compani
solubl formul metastat breast cancer
melanoma solubl dimer fusion protein consist fc portion
human antibodi four-extracellular domain engag mhc
class ii express surfac antigen present cell apc solubl induc
function matur dendrit cell power antigen-pres cell
immunostimulatori respons potenti enhanc activ standard
care treatment current use metastat melanoma breast cancer
preliminari data phase tacti-mel melanoma trial demonstr
overal respons rate phase iib aipac breast cancer studi demonstr
aipac compani addit plan begin studi
combin candid inhibitor
initi
initi
data fourth patient cohort tacti-mel
final progress free surviv data aipac
preliminari data readout
analyst certif disclosur pleas see page
strong interest surround applic recent garner interest
oncolog industri simultan immuno-suppress immuno-stimulatori properti also open
possibl applic auto-immun disord number patient evalu
candid steadili rose less approxim alongsid growth
number clinic trial studi therapeut prevail big pharma interest highlight immutep
secur licens agreement novarti bristol-my squibb develop relatlimab big
player like merck regeneron develop inhibitor bristol-my squibb relatlimab
furthest along clinic develop current evalu phase ii/iii trial phase i/iia data
opdivo relatlimab combin patient relaps refractori melanoma present esmo
demonstr overal respons rate increas analysi conduct amongst
patient express least tumor-associ immun cell within tumor margin immutep
posit one leader develop therapi program clinic develop
two out-licens partnership novarti glaxosmithklin
final progress free surviv data aipac expect aipac on-going phase iib
studi use combin standard chemotherapi paclitaxel patient metastat breast
cancer studi enrol patient phase safeti run-in portion anticip enrol addit
double-blind phase ii portion compani announc mid-point patient enrol
reach june preliminari result safeti run-in portion present overal
dose combin paclitaxel safe well-toler
seriou treatment-rel advers event grade cytokin releas syndrom primari endpoint
phase ii portion assess progress free surviv time period month
secondari endpoint includ safeti toler assess chang qualiti life evalu
object respons rate evalu stabl diseas efficacy-rel endpoint analyz sole
patient enrol stage progress free surviv data anticip
three potenti area applic immutep develop therapeut three
pivot area application- part chemotherapy-immunotherapi combin part io-io
combin potenti vaccin adjuv potenti chemo-io combin regimen
demonstr approv pembrolizumab chemotherapi nsclc co-administr
chemotherapi potenti demonstr addit effect increas circul presenc
activ dc readi uptak tumor antigen cell die result chemotherapy-induc immunogen
rational behind combin thought take brake
immun system simultan push acceler checkpoint inhibitor treatment
method combat loss immunogen increas immun detect cancer cell mask
inhibitori receptor co-administr could increas popul prime circul
readi attack unmask tumor cell enhanc efficaci checkpoint inhibitor lastli cancer vaccin
adjuv boost desir respons otherwis weak antigen also associ toler
mechan one mechan overcom immunosuppress barrier potent recruit
activ antigen present cell either prime activ pre-exist adapt immun response-
potenti key function
full year result immutep report revenu equal usd year
end june refer attribut two signific mileston payment novarti
eoc pharma research develop expens usd compar
usd corpor administr expens increas usd fy
usd fy after-tax loss usd compar
after-tax loss usd fy translat dilut loss per share usd
compar dilut loss per share usd fy compani
cash cash equival usd june
second quarter financ share purchas march immutep announc
success complet placement ordinari share variou australian us
institut investor includ platinum asset manag australian ethic ridgeback capit
invest placement gener total usd prior transaction-rel expens
subsequ compani announc close share purchas april spp
success place new ordinari share usd per share gener
usd transaction-rel expens togeth two financ event rais total
tabl content
collabor partnership
eftilagimod alpha apc activ treatment cancer
mechan action
potenti combin immunotherapi
market inform non-respond
market inform melanoma patient respond inhibitor
clinic data discuss melanoma
tacti-mel activ immunotherapeut melanoma
clinic data discuss metastat breast cancer
clinic trial
activ immunotherapeut differ indic
immuno-oncolog drug develop
competit landscap oncolog
antagonist treatment cancer
candid develop
auto-immun diseas
deplet antibodi autoimmun diseas
risk invest
immutep immp clinical-stag biotechnolog compani focus develop lag-
relat immuno-therapeut lymphocyt activ gene origin discov
compani chief medic scientif offic frdric triebel sinc character
power antigen-pres cell activ well neg regul t-cell pre-clin clinic
studi shown solubl induc potent matur apc reduc tumor burden
increas present tumor antigen apc context cancer vaccin adjuv
compani develop lead therapeut eftilagimod alpha three pivot area chemo-
immunotherapi combin immunotherapy-immunotherapi combin vaccin adjuv
uniqu immuno-stimulatori immuno-suppress properti allow immutep develop
uniqu product candid immuno-oncolog autoimmun diseas compani
development pipelin shown figur
eftilagimod alpha solubl fusion protein current evalu multipl
clinic trials-aipac tacti-mel insight aipac evalu combin
chemotherapi treatment metastat breast cancer tacti-mel evalu co-administr
therapi metastat melanoma preliminari data although earli support
continu evalu agent preliminari data melanoma trial demonstr
overal respons rate breast cancer studi demonstr diseas control rate upon
preliminari analysi march immutep enter clinic trial collabor suppli agreement
merck nyse initi phase ii trial assess combin
keytruda hnscc nsclc trial anticip initi recent compani
announc anoth clinic trial collabor suppli agreement merck kgaa initi
phase trial assess combin inhibitor bavencio avelumab
variou solid tumor immutep exclus world-wid right develop us
eu eoc pharma hold exclus right develop commerci product mainland china
hong kong taiwan macau part mileston royalty-bas licens agreement eoc pharma
initi phase studi metastat breast cancer china immutep also secur multipl
big-pharma licens agreement surround two clinical-stag asset
out-licens novarti nyse nv signific undisclos amount up-front mileston
payment out-licens glaxosmithklin nyse gsk agreement make immutep
elig mileston well single-digit tier royalti
collabor partnership
immutep secur extens number partnership collabor surround
product candid multipl licens agreement collabor relat lead asset
immutep exclus world-wid right develop us eu
eddingpharm privat held exclus right develop commerci product mainland china
hong kong taiwan macau part licens agreement establish agreement
transfer eoc pharma affili eddingpharm agreement immutep elig
mileston payment royalti although concret detail remain undisclos compani receiv
first mileston payment eoc pharma februari total
immutep announc collabor agreement cytlim spin-off nec corpor
pinx nipnf test combin cancer peptid vaccin new materi transfer
agreement revenue-gener immutep compani provid formul
develop use clinic pre-clin trial conduct cytlim
addit immutep strateg suppli partnership wuxi biolog subsidiari wuxi apptech
co ltd shanghai exclus manufactur march
compani enter clinic trial collabor suppli agreement merck conduct
new phase ii clinic trial evalu combin keytruda patient hnscc
nsclc addit septemb immutep announc anoth clinic trial collabor suppli
agreement merck kgaa assess efficaci combin avelumab
antibodi patient advanc solid malign collabor serv
amend current on-going insight studi
compani two clinical-stag asset out-licens two big pharma compani
initi out-licens acquir novarti part
origin agreement novarti hold exclus world-wid right develop cancer
immutep elig undisclos amount up-front mileston payment well royalti base
world-wid sale novarti paid two mileston payment date compani execut
licens agreement glaxosmithklin grant gsk exclus world-wid right develop
autoimmun disord agreement make immutep elig
up-front mileston payment well single-digit tier royalti compani receiv first
mileston payment gsk initi phase clinic trial anticip anoth
potenti upcom mileston payment base gsk public announc initi clinic proof
concept studi coliti
lymphocyt activ membrane-protein mhc class ii ligand respons
multipl role within immun system includ t-cell inhibit regul dendrit cell
function structur genet relat protein possess differenti
characterist bind mhc class ii molecul higher affin transduc
signal protein tyrosin kinas lck express induc activ t-
cell correl abil secret interferon- ifn- make one known marker
express surfac activ t-cell immutep design multipl uniqu approach
therapeut use leverag immunostimulatori immunoinhibitori properti solubl
shown possess immunostimulatori properti modul
activ antigen present cell apc hand natur establish co-inhibitori
receptor whose express activ t-cell known potenti inhibitori effect cell
translat overal immunoinhibitori respons uniqu characterist give target agent
potenti applic across oncolog auto-immun diseas
immuno-stimul tumor cell develop varieti cellular mechan evad
suppress elimin immun system one mechan loss antigen sever
loss antigen result defect antigen present deriv lack tumor antigen
express downregul mhc molecul alter mhc-antigen load also caus
downregul costimulatori molecul result hamper mhc signal
immuno-stimulatori effect come role apc activ although nucleat cell
consid antigen-pres cell matur apc initi specif immun respons prime
nave t-cell specif dendrit cell regard most-pow antigen-pres cell
uniqu abil induc primari immun respons solubl recombin fusion protein
shown induc phenotyp matur immatur dendrit cell ligat mhc class ii
matur apc increas express mhc class mhc class ii molecul well increas
express co-stimulatori molecul although cell gener recogn
antigen present mhc class matur apc also present mhc class ii- associ exogen
antigen t-cell cross-present therefor induc increas matur
dendrit cell up-regul result physiolog improv antigen
 gladney immun escap mechan guid cancer immunotherapi clinic
et al turn tumor cell antigen present cell next step improv cancer
immunotherapi european journal cancer pp
et al matur activ dendrit cell induc lymphocyt activ journal
immunolog pp
present cell potenti counteract loss antigen tumor util
immuno-suppressor asid loss antigen loss immunogen
gener immuno-suppress tumor microenviron also wide accept altern
mechan tumor immun evas propag tumor upregul certain immun
checkpoint lead inhibit cell activ immun checkpoint
implic key contributor t-cell exhaust cancer result impair tumor kill abil
checkpoint inhibitor therapi becom promis therapeut target har immun system
fight cancer identifi cancer potenti suscept immunotherapi howev
diminish efficaci current ici led increas need pinpoint immun checkpoint
molecul neg regulatori marker
solubl role apc activ natur emerg relev checkpoint
molecul involv neg regul t-cell process t-cell activ mark
biochemical/biophys reprogram meet higher energet demand associ activ
one reprogram requir chang metabol statu shown distinct
metabol state character nave matur t-cell ligat tcr peptide/mhc complex
stimul multipl signal cascad includ one result downstream mobil calcium
result calcium signal thought play key role modul downstream pathway
involv metabol shift simultan cross-link complex
shown hamper increas calcium flux confirm neg regulatori although
exact signal pathway evok interact remain unclear uniqu univers conserv
kieel motif shown essenti inhibitori function protein bind particular motif
yet elucid
eftilagimod alpha apc activ treatment cancer
mechan action eftilagimod alpha solubl recombin formul known
dimer fusion protein consist fc portion human antibodi
four-extracellular domain figur depict structur key role solubl lag-
activ antigen present cell therebi produc immunostimulatori respons
 et al modul t-cell metabol function calcium signal frontier
 et al tigit co-inhibitor receptor special function immun
shown induc phenotyp function matur dendrit cell power
antigen-pres cell confirm role apc activ uniqu bind subset mhc
class ii molecul local cholesterol-rich lipid raft presum contain transduc protein
facilit downstream mhc class ii signal bind induc upregul
well morpholog chang confirm transit immatur matur dendrit cell
key secondari compon dc matur migrat dc secondari lymphoid organ
acquir potent immunostimulatori properti go sensit nave antigen-specif t-cell therebi
promot primari immun respons shown abil induc secret cytokin
essenti migratori induced-matur result upregul dc receptor
constitut chemokin essenti home lymph node simultan down-
regul receptor inflammatori cytokin addit result up-regul
costimulatori molecul signal involv determin whether nave antigen-specif t-cell
becom immun toler up-regul may therefor increas immunogen antigen-load
matur dc lead effici antigen-present
safeti profil overal treatment appear safe well-toler dose-limit
toxic treatment-rel discontinu report common advers event relat
across conduct clinic trial grade local erythema inject site reaction
dose appear well-toler administ combin paclitaxel dose
level appear well-toler administ combin pembrolizumab aipac trial
grade cytokin releas syndrom seriou treatment-rel advers event report help
confirm immunostimulatori effect patient aipac trial patient
tacti-mel trial experienc grade advers event pre-clin toxicolog studi assess three
triebel mhc class ii engag ligand lead distinct pattern
chemokin chemokin receptor express human dendrit cell vaccin pp
inject maxim dose per kg use phase trial lead detect toxic
sign
efficaci treat cancer non-immunogen undifferenti
spontan mammari adenocarcinoma ts/a cell line use tumor model differ concentr
recombin solubl human mous test statist
signific growth rate reduct observ wild-typ tumor cell inject
 interestingli dose perform administ
higher dose statist signific growth reduct seen dose level
effect administr tumor growth depict figur dose variat
mous human result could due protein fold half-lif differ
data demonstr potenti induc anti-tumor effect non-
figur effect administr tumor growth
assess whether cell surfac express could affect tumor growth three tumor line transfect
cdna three tumor line mca ts/a renca
immunogen renal adenocarcinoma balb/c t-cell defici balb/c nu/nu mice
subcutan inject minimum tumorigen dose either wild-typ transfect tumor
cell wild-typ tumor line grew progress either three mous model contrast
cell form palpabl tumor immunocompet mice
cell line grew progress immune-defici nu/nu mice level
similar wild-typ cell signific portion mice express contribut tumor
regress decreas growth cell compar wild type tumor growth
reduct associ tumor cell express shown figur
et al solubl protein immunopotenti therapeut vaccin preclin
evalu vaccin pp
 et al lymphocyt activ induc tumor regress anti-tumor immun respons
european journal immunolog pp
balb/c mice inject wild type ts/a renca cell order assess efficaci
treatment irradi tumor cell mice treat day either
ts/a renca cell reduct tumor growth seen case across tumor type
case demonstr complet regress inject irradi tumor cell
demonstr potenti vaccin adjuv balb/c mice subcutan
inject minim tumorigen dose either mous fibrosarcoma cell metastat mous
adenocarcinoma ts/a cell mice treat subcutan inject irradi tumor cell sourc
antigen without treatment administ either day
twice day co-administr reduc tumor growth tumor
model oppos treatment irradi cell alon pb result mice treat mice
treat twice similar re-challeng mice day minimum tumorigen dose wild-typ
tumor cell show specif tumor-immun respons maintain tumor growth lower
mice previous inject cell protect re-challeng also
observ ts/a renca cell similar studi test potenti vaccin
adjuv demonstr induc similar matur level compar known induc
apc activ potenti safeti advantag clinic develop
hamper associ risk
et al solubl protein immunopotenti therapeut vaccin preclin
evalu vaccin pp
induc tumor reject mediat t-cell diamet tumor excis
day normal host inject mca ts/a cell
percentag cell mca tumor compar wild type mca
tumor respect contribut cell anti-tumor respons measur
deplet individu subset deplet cell lead partial abrog tumor protect
deplet cell led complet loss tumor cell reject addit studi demonstr
peptide-specif t-cell gener presenc endow strong cytotox
activ enhanc releas type cytotox cytokin ifn- well character
final effector memori
potenti combin immunotherapi
divers function uniqu mechan action potenti use
variou combin therapi shown figur compani current develop three
potenti combin chemo-io combin io-io combin adjuv cancer vaccin
figur area applic
chemotherapy-immunotherapi combo potenti chemo-io combin regimen
demonstr approv pembrolizumab chemotherapi nsclc chemotherapeut agent
induc immunogen death tumor cells- type cell death prime anti-canc immun respons
cell death -induc chemotherapeut gener begin er stress promot
transloc calreticulin crt plasma membran pre-apoptot succeed
releas damage-associ molecular pattern damp molecul alongsid variou tumor antigen
 et al solubl human molecul amplifi vitro gener type tumor-specif
et al effect chemotherapy-induc tumor cell death gene diseas pp
avail on-line
die tumor cell damp molecul stimul recruit dendrit cell play pivot role
uptak process present releas tumor-antigen prime cytotox t-lymphocyt
effect mount anti-tumor immun respons co-administr chemotherapi
potenti demonstr addit effect two therapi amplifi immun respons
alreadi gener chemotherapi alon power activ antigen-pres cell
increas circul presenc activ dc readi uptak tumor antigen die tumor cell
result physiolog increas antigen present
immuno-immunotherapi combo rational behind combin
thought take brake immun system simultan push acceler anti-
checkpoint inhibitor work block interact cell tumor
lead inhibit t-cell activ treatment method combat loss immunogenicity-
one main immun escap mechan use tumor co-administr combin
checkpoint inhibitor design simultan target anoth well-establish immun escap mechanism-
loss antigen serv dendrit cell activ yield matur dendrit cell
upregul increas popul matur apc intend increas effici
antigen present result increas prime circul readi attack
adjuv cancer vaccin vaccin adjuv serv purpos enhanc magnitud longev
specif immun respons induc antigen present within specif cancer vaccin
use adjuv necessari boost desir respons otherwis weak antigen also
associ toler mechan one mechan overcom immunosuppress barrier
hallmark tumor potent recruit activ antigen present cell either prime
skew pro-inflammatori respons central vital effect therapeut vaccin strategi
demonstr potenti gener specif immun addit function potent dendrit
cell activ pre-clin studi mous fibrosarcoma metastat adenocarcinoma model demonstr
co-administr vaccin irradi tumor cell reduc tumor growth oppos
vaccin alon result maintain specif tumor-immun respons upon re-challeng day
result support investig potenti vaccin adjuv
market inform non-respond
although initi studi treatment melanoma triple-neg breast cancer
potenti util combin treatment checkpoint inhibitor could expand tumor type
checkpoint inhibitor effect compar convent therapi sever tumor type mani
patient respond treatment option often limit follow progress broad respons
rate inhibitor approv indic present figur respond
progress could repres sizeabl market opportun immutep respons rate
base prescrib label publish literatur opdivo keytruda bavencio
 reed adjuv cancer vaccin seminar immunolog pp
first-lin nsclc express
chemotherapi keytruda advanc nsclc
relaps progress classic hodgkin lymphoma
hsct
local advanc metastat urotheli carcinoma
unfit cisplatin-chemotherapi
recurr metastat cervic cancer
figur respons rate approv indic
unresect metastat melanoma
includ monotherapi combin
combin
market opportun combin agent highlight nektar/bristol-my squibb
collabor due vast-numb patient benefit checkpoint inhibitor
great interest pharmaceut compani investor combin agent highlight
collabor bristol-my squibb announc
earli receptor beta subunit bias agonist preliminari phase i/ii data
show encourag respons rate treatment nave melanoma nsclc treatment nave
rcc treatment nave urotheli carcinoma includ neg tumor follow earli
data bristol-my squibb enter global develop commerci collabor nektar
term agreement nektar receiv up-front payment billion
 cash stock elig receiv addit billion mileston compani
share global profit nektar receiv develop cost also share
two compani evalu combin opdivo indic
tumor type size collabor give indic premium big pharma will pay
novel therapi
melanoma cancer pigment-produc skin cell known melanocyt gener caus
combin genet risk factor ultraviolet light exposur sun estim new case
melanoma diagnos us patient die diseas addit
diagnos expect eu melanoma make total cancer diagnos
account roughli skin cancer although nearli peopl diseas cure
identifi earli surviv patient grade melanoma patient
grade iv diseas grade iv melanoma make least case diseas
us caucasian male histor highest risk melanoma follow caucasian white
femal sun exposur light skin pigment contribut significantli develop melanoma
howev melanoma possibl type skin area bodi typic receiv sun
certain gene commonli mutat melanoma may specif tie pathogenesi
commonli mutat gene melanoma found case braf encod
intracellular protein protein part broader signal transduct pathway map kinas
mapk pathway often alter melanoma
treatment melanoma initi treatment melanoma gener involv excis malign tissu
sinc type cancer aggress invad surround tissu extent tissu excis
depend stage cancer found surgeon perform excis tri remov
cancer tissu minim damag surround healthi tissu gener involv level
guesswork due need ensur cancer cell remain boundari set surgeon tend
aggress
stage melanoma near cure rate due well surgeri remov full lesion advanc
melanoma difficult treat usual requir substanti amount tissu remov ensur
full extent cancer tissu excis melanoma spread inoper system
immunotherapi like bristol-my squibb opdivo nivolumab /- yervoy ipilimumab merck nyse
keytruda pembrolizumab often use agent also carri substanti cost roughli
per year combin
case patient progress respond inhibitor agent yervoy target therapi
specif cancer-caus mutat chemotherapi drug clinic trial recommend roughli
half melanoma mutat braf gene patient mutat either prescrib
braf inhibitor first-lin treatment follow progress checkpoint inhibitor novarti nyse
nv tafinlar dabrafenib roch vtx rog vx zelboraf vemurafenib array biopharma
arri braftovi encorafenib braf inhibitor approv treatment
melanoma often combin mek inhibitor mekinist trametinib cotel cobimetinib mektovi
binimetinib due increas efficaci also note small number patient receiv amgen
siegel et al cancer statist ca cancer journal clinician
ncnn clinic practic guidelin oncolog melanoma
oncolyt viru imlyg t-vec although use may increas approv
combin inhibitor
market inform melanoma patient respond inhibitor
epidemiolog american cancer societi estim peopl us diagnos
melanoma die diseas addit estim case
diagnos annual melanoma patient diagnos stage iv
diseas estim elig patient prescrib inhibitor make potenti
candid immutep surviv rate patient stage melanoma
patient grade iv diseas expect surviv rate improv patient receiv
immunotherapi melanoma patient respond frontlin
translat new patient annual could receiv us
around eu also note complet respons rate checkpoint
inhibitor melanoma mani patient initi respond
clinic data discuss melanoma
tacti-mel activ immunotherapeut melanoma
studi design open-label dose-escal phase studi combin
therapi pembrolizumab patient unresect metastat studi consist two
part dose administ part defin dose-escal conduct part
anticip enrol patient divid cohort patient elig patient character
demonstr diseas progress sub-optimal respons pembrolizumab monotherapi
import note patient respons pembrolizumab evalu cycl treatment even
though median time respons associ pembrolizumab approxim cycl patient
enrol part receiv subcutan inject either mg mg mg everi week
begin cycl pembrolizumab treatment part flow diagram depict figur
subsequ patient enrol part receiv subcutan inject everi week
begin day pembrolizumab treatment pembrolizumab treatment administ
intraven dose mg/kg everi week note previous repres sub-optim dose
pembrolizumab mg/kg soc recent amend flat dose howev
mg/kg standard dose use australia trial conduct
 et al overal surviv combin nivolumab ipilumumab advanc melanoma
new england journal medicin
primari endpoint studi assess recommend phase ii dose safety/toler
secondari endpoint includ progression-fre surviv overal surviv part best overal
respons rate time next treatment compani announc complet patient enrol part
 august preliminari data fourth cohort anticip respons
preliminari studi result preliminari result part studi present
perform analysi result collect initi combin therapi best overal respons
rate analyz efficaci initi start pembrolizumab day overal
respons rate note respons analyz use immune-rel respons criteria irrc
oppos tradit use recist criteria given key differ two
guidelin harder interpret comparison efficaci result pembrolizumab monotherapi
well efficaci result clinic trial breakdown degre respons depict figur
tumor shrinkag note patient patient demonstr complet disappear
figur respons rate combin pembrolizumab
combin cycl
respons rate cycl
pembrolizumab
patient enrol first two cohort demonstr durabl respons durat
month treatment follow-up still on-going cohort patient progress
free start pembrolizumab treatment gener safe well-toler total
sever advers event note deem possibl treatment-rel
treatment-rel grade advers event note one patient consist grade decreas renal
function grade maculopapular rash major treatment-rel advers event grade
common one local erythema inject site reaction dose-limit toxic ae-
relat treatment discontinu observ
breast cancer common form cancer affect women breast-canc type
determin specif breast cell affect major breast cancer carcinoma tumor
start epitheli cell line organ tissu bodi breast-canc diagnos repres
approxim new cancer case estim diagnos occur us
deleteri mutat within gene correspond significantli higher risk
develop breast cancer mutat associ lifetim risk
mutat associ lifetim risk diseas although rel surviv rate
early-stag breast cancer almost surviv rate drop stage breast cancer
metastat stage iv cancer
breast-canc group distinct subtyp uniqu gene express pattern translat differ
molecular profil patholog featur clinic outcom lumin tumor character posit
express low lumin tumor character posit er/pr
express neg express high enrich tumor exhibit overexpress
receptor basal-lik tumor also known triple-neg breast cancer associ neg
express er pr er/pr statu strongest predict factor respons endocrin
therapi express predict factor respons certain therapi option target
receptor also known prognost factor outcom node-neg node-
posit patient node statu determin presenc absenc cancer cell breast tumor
lymph node amplif node-posit breast cancer shown correl earlier
relaps shorter overal surviv addit implic independ indic increas
risk recurr diseas node-neg breast although basal subtyp breast cancer
found case neg indic poor prognosi
target therapi current avail
 et al pathogenesi prevent diagnosi treatment breast cancer world journal clinic
 et al express node-neg breast cancer direct tissu quantit
computer imag analysi associ overexpress increas risk recurr diseas cancer research
 et al basal breast cancer complex deadli molecular subtyp current molecular medicin
treatment option diagnosi patient clinic stage use american joint commiss
cancer ajcc guidelin breast-conserv therapi bct gener consist conserv
lumpectomi follow radiotherapi consid recommend treatment option early-stag breast
cancer absolut contraind bct includ multicentr diseas diffus malignant-appear
calcif inflammatori breast cancer inelig receiv radiat approxim us
breast-canc patient mastectomi candid either choic inelig bct appropri
treatment decis also influenc receptor schemat standard care therapeut
option differ breast-canc subtyp shown figur
figur standard therapeut option breast cancer
santa-maria gradishar
first-lin therapi triple-neg breast cancer gener chemotherapi target therapi option
current exist subtyp front-lin therapi er/pr posit tumor cyclin-depend kinas
inhibitor endocrin therapi specif nyse ibranc palbociclib combin
novarti nyse nv femara letrozol option er/pr posit tumor includ altern
combin endocrin therapi chemotherapi cyclin-depend kinas inhibitor prefer first-
line regimen tumor combin therapi genentech herceptin
trastuzumab genentech perjeta pertuzumab chemotherapi consist taxan patient
progress combin administ genentech kadcyla trastuzumab emtansin
prefer second line treatment patient tumor posit er/pr treat
either endocrin therapi monotherapi combin clinic relev
epidemiolog estim new breast cancer patient diagnos us
repres approxim newli diagnos cancer case addit estim
patient die breast-canc base incid per new case
 gradishar chang treatment paradigm metastat breast cancer jama
breast cancer diagnos europ current surviv rate individu stage
iv breast cancer despit advanc hormon driven breast cancer current treatment
option besid chemotherapi avail triple-neg breast cancer associ poor
prognosi unrespons standard treatment although current approv indic
clinic trial test efficaci immun checkpoint inhibitor metastat breast cancer shown
promis respons rate approxim newli diagnos breast-canc
patient diagnos triple-neg subtyp make elig receiv improv
treatment efficaci translat annual patient popul us patient
popul eu
clinic data discuss metastat breast cancer
studi design on-going random double-blind placebo-control phase iib studi
combin standard chemotherapi paclitaxel patient metastat breast estim
patient random receiv either paclitaxel placebo paclitaxel patient
begin treatment standard cycl chemo-immunotherapi consist weekli paclitaxel
day combin either placebo day cycl
complet chemo-immunotherapi phase respond stabl patient continu receiv
either placebo everi week mainten phase addit inject
studi consist two stage stage open-label safeti run-in consist cohort confirm
recommend phase two dose rptd combin paclitaxel stage placebo-control
double-blind random stage evalu paclitaxel confirm rptd primari
endpoint stage one determin rptd key secondari endpoint stage evalu
pharmacokinet primari endpoint stage assess progress free surviv
time-period month secondari endpoint includ safeti toler
assess chang qualiti life evalu object respons rate evalu stabl diseas
efficacy-rel endpoint analyz sole patient enrol stage compani present
result safeti run-in stage studi current mid-way enrol
preliminari studi result stage safeti run-in stage patient receiv
inject overal mg dose mg dose appear safe well-toler
combin paclitaxel seriou treatment-rel advers event grade cytokin releas
syndrom grade inject site reaction common advers event relat
patient experienc relat grade advers event
term efficaci patient demonstr partial respons patient stabl diseas yield
overal diseas control rate overal respons rate pharmacodynam analysi
 checkpoint inhibitor breast cancer chang therapeut landscap asco daili news
valid mechan action shown figur treatment induc increas
number circul antigen-pres cell includ monocyt peripher dendrit cell myeloid
dendrit cell addit treatment induc earli sustain increas
biomark well increas absolut number effector cell includ activ
figur induc increas circul apc
clinic trial
activ immunotherapeut differ indic
studi design multi-cent open-label singl arm phase ii studi combin
pembrolizumab nsclc studi follow simon two-stag design enrol
approxim patient three sub-ind previous untreat unresect metastat non-
small cell lung cancer recurr refractori non-smal cell lung cancer metastat squamou
head neck cancer patient receiv pembrolizumab everi week combin
mg everi week first cycl everi week start cycl primari endpoint
evalu object respons rate accord irecist criteria secondari measur includ
durat frequenc sever advers event time respons durat respons diseas control
rate progress free surviv overal surviv respons rate response-rel key secondari endpoint
evalu use recist irecist criteria studi conduct part clinic
trial collabor suppli agreement merck patient recruit anticip commenc prior
end
studi design open-label investigator-initi explor phase studi patient
advanc solid tumor studi consist three strata studi scheme shown figur
strata a/b includ patient either fail refus intoler toward standard therapi
patient solid tumor access repeat inject part stratum receiv bi-weekli
intra-tumor inject dose done dose escal mg
first cohort patient addit periton carcinomatosi part stratum receiv
biweekli intraperiton inject dose done dose escal
mg first cohort patient cohort show treatment benefit last direct inject
offer mainten treatment consist subcutan inject week
stratum enrol patient receiv standard care therapi receiv biweekli subcutan
inject mg primari endpoint studi feasibl rate rate patient
receiv treatment without incur dose-limit toxic secondari endpoint includ incid
sever aes/sa object respons rate progress free surviv overal surviv june
patient enrol stratum dose-escal accomplish patient patient
enrol stratum data singl case studi made avail throughout
septemb immutep enter anoth clinic trial collabor merck kgaa
conduct phase studi evalu combin avelumab serv amend
insight trial recommend phase ii dose avelumab studi patient
advanc solid malign exist insight studi protocol
immuno-oncolog drug develop
follow initi approv checkpoint inhibitor field immunotherapi drug develop
quickli grown howev overal lack efficaci major patient driven big pharma interest
develop combin therapi provid increas clinic benefit current
combin studi on-going checkpoint inhibitor approv immunotherapi
combin treatment involv therapi melanoma renal cell carcinoma
chemotherapi therapi lung cancer sever treatment develop combin
checkpoint inhibitor one interest list figur notabl therapi
administ intratumor inject could limit use invas tumor type
figur select combin treatment develop
mechan
phase
multi-tki
class iv
tumor
sq ip
competit landscap oncolog
gain increas interest includ develop bristol-
myer squibb relatlimab co-inhibitori receptor receiv strong therapeut interest
novel immun checkpoint stand alongsid prevail big pharma interest
highlight immutep secur licens agreement novarti bristol-my squibb develop
relatlimab big player like merck regeneron develop inhibitor phase i/iia
data assess bristol-my squibb antibodi relatlimab opdivo patient melanoma
relaps refractori therapi present esmo result show
overal respons rate evalu patient although patient express
least tumor-associ immun cell within tumor margin overal respons rate
compar less express patient express
tumor cr interestingli express lead better patient respons base
result fact inhibitori checkpoint intrigu potenti target term
safeti treatment gener well toler similar would expect inhibit
alon treatment relat death report patient discontinu treatment due treatment
activ may better understood futur studi base tacti-mel trial design
immutep present updat preliminari data tacti-mel studi may studi evalu
combin pembrolizumab patient metastat melanoma report overal
respons rate progression-fre rate month elig patient popul
studi intend patient demonstr sub-optimal respons keytruda
monotherapi elig screen conduct patient receiv cycl keytruda treatment
howev import note median time respons report keytruda approxim
treatment cycl addit trial util mg/kg dose keytruda previous repres
sub-optimal dose report overal respons rate show mark improv overal
respons rate encount mg/kg keytruda monotherapi notabl tacti-mel respons rate analysi
conduct context immune-rel respons criteria irrc differ tradit
use recist criteria irrc guidelin make difficult demonstr complet partial respons
simultan looser interpret stabl progress diseas present obstacl
place result context clinic trial
subcutan administr may offer preferenti method deliveri previous
note combin therapi develop use intratumor deliveri method could
limit use certain tumor type addit major approach develop util
intraven drug deliveri immutep purs develop subcutan inject well
studi intratumor intraperiton inject patient-prefer studi reveal patient clearli
prefer subcutan deliveri highlight deliveri method could provid posit point
differenti
apc activ approach develop approach develop activ
antigen present cell includ agonist toll-lik receptor tlr agonist stimul interferon
gene sting agonist oncolyt viral therapi sting pathway involv sens foreign
dna facilit gener type interferon immun respons bind ligand sting
protein result secret type interferon ifn pro-inflammatori cytokin act downstream
activ antigen-pres cell anoth approach studi activ apc use
antibodi solubl ligand bind costimulatori molecul either antibodi ligand
strongli activ apc approach also associ increas safeti concern
previous implic increas risk tlr-agonist similar mechan
action bind tlr result stimul antigen present cell lead product
pro-inflammatori cytokin activ cytotox t-lymphocyt b-lymphocyt immun respons
antagonist treatment cancer
human monoclon antibodi bind inhibit lag-
class ii interact cell-surfac marker express surfac activ t-cell
implic neg regul t-cell signal function high level express
associ develop exhaust t-cell character variabl deficit prolifer
 et al solubl ligand induc integrin tyrosin phosphoryl trigger
platelet activ outside-in signal pna pp
effector function typic seen cancer immunosuppress effect thought
mediat simultan cross-link complex yield decreas
calcium flux inhibit t-cell prolifer inhibitori receptor
central focu develop immun checkpoint inhibitor therapi howev efficaci
realiz subset patient driven increas interest inhibitori receptor
combin therapi emerg novel immun checkpoint inhibitor potenti addit
benefit combin co-blockad novarti receiv exclus world-wid right
licens agreement immutep elig undisclos amount regulatori
develop mileston well royalti base world-wid sale case approv
compani receiv two mileston payment relat develop date
current evalu on-going clinic trial run novarti
phase i/ii studi advanc solid tumor
two-part open-label phase i/ii studi character safeti toler preliminari efficaci
singl agent combin novarti monoclon antibodi pdr-
studi enrol approxim adult patient part enrol patient
advanc solid tumor part enrol patient varieti cancer includ nsclc melanoma
rcc mesothelioma tnbc part studi dose-escal phase determin either
maximum toler dose recommend phase two dose rptd part studi dose
expans phase studi singl agent combin
rptd singl agent dose either mg/kg everi two week
mg/kg everi week dose combin spartalizumab conduct dose
levels/schedul rang mg/kg mg/kg spartalizumab everi two week mg
mg spartalizumab everi week primari endpoint part incid dose-
limit toxic primari endpoint part overal respons rate accord recist
criterion secondari endpoint across phase includ addit safeti measur pharmacokinet
pharmacodynam measur diseas control rate progress free surviv durat respons
preliminari result januari patient receiv monotherapi
patient receiv combin therapi discontinu treatment treatment
discontinu primarili due progress diseas repres single-ag arm
combin therapi patient studi arm experienc dose-limit toxic
shown figur common advers event fatigu nausea single-ag arm
fatigu diarrhea nausea combin arm seriou treatment-rel
note patient single-ag arm combin arm respect
et al phase i/ii studi spartalizumab patient advanc
malign abstract present
figur incid character dose-limit toxic
term efficaci complet partial respons observ evalu patient one
complet respons ad partial respons complet respons note thymoma patient treat
mg spartalizumab mg partial respons seen follow indic
cervic cancer urotheli carcinoma gastric cancer prostat cancer unknown primari
respons note across broad rang dose level schedul although appar dose
depend correl also note respons note patient treat
monotherapi wherea immun checkpoint inhibitor shown singl agent
respons part portion on-going evalu combin spartalizumab select
indic includ tripl neg breast cancer mesothelioma
phase ii studi patient relapsed/refractori soc
open-label parallel-cohort phase ii studi spartalizumab combin
multipl tumor type relapsed/refractori avail standard target sub-
indic small-cel lung cancer gastric adenocarcinoma esophag adenocarcinoma castration-resist
neuroendocrin tumor diffus larg b-cell lymphoma studi initi enrol indication-specif
cohort patient cohort expand patient conting satisfi pre-
determin expans criteria patient receiv intraven
infus minut everi week maximum treatment time year two primari
endpoint clinic benefit rate evalu week progress free surviv month
secondari endpoint includ safety/toler time respons overal respons rate durat respons
time progress month patient enrol may futil analysi
conduct clinic benefit rate data avail patient cohort
addit phase ii studi
april novarti announc initi two addit studi includ among
evalu combin treatment one open-label three-arm multi-cent phase ii studi evalu
three potenti combin carboplatin patient advanc triple-neg
breast patient random receiv one three combin everi
day spartalizumab everi day everi day spartalizumab everi
day carboplatin dose per auc everi day everi day carboplatin
dose per auc everi day primari endpoint overal respons rate time-fram
measur recist criterion studi open-label phase ii trial assess variou pdr-
combin previous treat unresect metastat melanoma one
combin spartalizumab treatment arm receiv
mg spartalizumab intraven everi week primari endpoint overal respons rate
month time frame measur recist
candid develop
recent garner interest oncolog industri howev simultan immuno-
suppress immuno-stimulatori properti open possibl applic auto-immun
disord well number clinic trial studi therapeut grow number patient
evalu candid rose less approxim immutep
posit one leader develop therapi program clinic
develop two out-licens partnership novarti glaxosmithklin figur
present overview candid develop bristol-my squibb relatimab
furthest along clinic develop current evalu phase ii/iii trial
figur candid develop
phase
auto-immun diseas
proper function immun system reli maintain fine balanc immune-activ
immune-inhibit insuffici inhibit immun respons result develop
autoimmun disord healthi individu self-react t-cell suppos inactiv delet
process known thymic select would predict presenc auto-react t-cell
highli unlik howev auto-react t-cell produc bodi
attenu tcr signal intens result decreas sensit thymic neg select escap
thymic select auto-react cell subset t-helper cell
specif implic pathogenesi organ-specif autoimmun disord t-helper cell produc
ifn- well-character pro-inflammatori cytokin pathogen activ attribut
evoc strong chronic inflammatori reaction improperli activ t-cell
associ express one marker identifi date present sole
activ t-cell result immutep believ viabl marker target immunosuppress
could elimin pathogen activ t-cell minim impact rest t-cell
et al detect t-cell respons ubiquit cellular protein autoimmun diseas scienc
 romagnami chapter role cell autoimmun autoimmun
addit highli express subpopul natur occur t-cell known
natur regulatori t-cell t-reg t-reg central ensur peripher toler potenti auto-
reactiv t-cell manag slip past thymic select exert immuno-suppress function
direct cell-cel contact depend manner event relat initi persist auto-
immun diseas alter gener t-reg inadequ inflammatori suppress gener direct
result imbal circul t-reg elucid confer t-reg regulatori activ
import contributor function cell make express t-reg
potenti target select manipul t-reg activ treatment autoimmun diseas
deplet antibodi autoimmun diseas
human monoclon antibodi specif lymphocyte-activ gene antibodi
possess antibody-depend cellular cytotox adcc properti mediat afucosyl
shown enhanc intend mechan action destruct
express activ t-cell presum involv autoimmun note express
activ natur regulatori t-cell central regul self-react t-cell higher level
activ effector t-cell howev tissu nk cell less present adcc mediat death t-
reg may occur much lower rate blood glaxosmithklin receiv exclus world-wid right
part licens agreement immutep elig receiv
regulatori develop mileston well royalti immutep previous receiv mileston
payment upon initi phase studi plaqu psoriasi sinc complet
data report howev compani anticip upcom mileston payment light
glaxosmithklin publicli announc plan conduct clinic proof-of-concept trial
coliti
human monoclon agonist antibodi develop therapeut use
autoimmun diseas posit first-in-class product therapeut area agonist antibodi
intend amplifi immunosuppress effect exert activ t-cell compani intend
pursu develop multipl autoimmun indic includ inflammatori bowel
diseas rheumatoid arthriti multipl sclerosi septemb compani announc
commenc cell-lin develop associ manufactur step signal progress toward
 et al less therapeut antibodi afucosyl anti-canc antibodi
immutep lead asset protect patent famili includ patent dosag regimen
method treatment differ assay combin therapi patent expir
protect patent famili consist patent composit matter
patent method treatment combin treatment expir
protect one patent famili expir includ patent composit matter
method treatment compani pre-clin asset protect one patent famili
includ patent composit matter method treatment expir compani
note patent elig extens term made avail certain circumst
compens delay obtain regulatori approv
mr voigt serv chief offic chief busi offic sinc appoint
ceo execut director juli extens experi corpor biotechnolog
sector previous work person assist member execut board allianz
insur mr voigt also work german invest bank net ipo ag area busi
develop german secur offer earli invest manag mid-size
healthcar ventur capit fund biotech sector held differ execut posit foremost
privat german biotech compani master degre busi administr freie
universitt berlin member judg panel germani largest busi plan competit
chief scientif offic chief medic offic
frdric triebel md ph found immutep serv scientif medic director
appoint immutep formerli prima biom chief medic offic chief
scientif offic follow acquisit immutep prima biom decemb
start immutep professor immunolog pari univers work institut gustav
roussi igr larg cancer centr pari discov gene subsequ research
identifi function medic use molecul head research group igr also
involv biolog follow-up cancer patient treat phase i/ii immunotherapi trial
director inserm first train clinic haematologist prof triebel
hold ph immunolog pari univers success develop sever research program
immunogenet immunotherapi lead public patent
ms miller join immutep gener counsel compani secretari octob promot
role chief oper offic novemb broad commerci experi held legal
invest bank regulatori complianc tax advisori posit includ legal counsel
investor servic associ director westpac group legal complianc manag macquari group
regulatori complianc analyst australian secur invest commiss tax advisor
kpmg join prima gener counsel compani secretari octob combin
bachelor honour bachelor commerc account financ doubl major
univers sydney admit solicitor nsw member law societi nsw
vice presid busi develop investor relat
mr campbel join immutep februari previous senior director busi develop
investor relat inc privately-held biotechnolog compani develop
biolog therapeut target receptor tyrosin kinas oncolog immunolog acquir
celldex therapeut inc decemb prior kolltan mr campbel spent year work
financi servic industri independ busi develop consult major
invest banker focus life scienc industri time mr campbel
busi develop consult inc connect compani review
strateg altern culmin sale compani bausch lomb mr campbel
previous work maxim group royal bank scotland abn amro rothschild schroder
throughout career work success financ licens transact
repres billion jay serv member board director updat pharma inc
privat held clinical-stag small molecul compani focus develop overlook underutil anti-
cancer drug receiv bsba manag bucknel univers minor spanish
director clinic develop regulatori affair
mr mueller bba work field clinic develop oncolog drug
decad join immutep complet master scienc technic
univers berlin join medic enzym ag focus therapeut enzym treatment
cancer respons deliver clinic phase ii studi built clinic team
took respons strateg clinic develop lead compound sinc work
ganym pharmaceut ag develop ideal monoclon antibodi field immun
oncolog respons clinic develop program lead antibodi setup
manag clinic team success complet multi-national random phase iib studi
patient investig lead antibodi combin chemotherapi patient advanc
metastat gastric cancer studi core asset billion usd trade sale deal astella
effort field clinic develop led sever public patent
director manufactur
dr jacobi join immutep year experi biotech industri prior
current role held variou posit pre-clin clinical-stag pharmaceut compani
gain comprehens experi protein express purif well analyt preclin
develop head biochemist head manufactur differ european biotech compani
develop supervis manufactur process conduct accord manufactur practic
gmp biolog small molecul interact contract manufactur organis ensur
suppli clinic trial phase ii parallel dr jacobi act independ medic writer
support compani regulatori interact clinic trial applic dr jacobi master degre
biochemistri complet phd institut martin-luther-univers
director manufactur
dr buchholz join immutep june year experi work biotechnolog
industri michael bring immutep extens experi biotechnolog manufactur well
relationship manag technolog supplier contract manufactur research organ
complet phd univers bath uk start career project manag cell therapi
manufactur contract manufactur organ site fraunhof institut
immunolog cell therapi leipzig germani gain signific experi
manufactur practic gmp join prima biom project manag manufactur
focu cell therapi manufactur cmo us australia germani michael promot
role director manufactur overse gmp complianc recombin protein product
china michael join cell medica head cell medica gmp manufactur facil
berlin germani focu cell therapi manufactur parallel michael act independ
lectur manufactur practic focal point biolog cell therapi manufactur
michael hold phd regen medicin univers bath uk biochemistri
free univers berlin germani
risk invest
consid invest immutep high-risk invest immutep develop stage compani
histori take treatment market current fda approv drug portfolio
sever compani tri target indic immutep cancer treatment
pipelin especi crowd competitor immutep lead program yet gener pivot data
limit clinic data date furthermor earli indic efficaci necessarili translat
posit late-stag result compani immutep may unabl obtain suffici capit fund
plan develop program regulatori risk associ develop drug
immutep may receiv fda approv candid despit signific time financi invest
regulatori approv market sell drug guarante drug penetr market
sale may meet expect investor
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
